VTRS Q4 2022 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B-10.7% YoY

Gross Profit

$1.3B32.9% margin

Operating Income

-$201M-5.2% margin

Net Income

$1.0B26.1% margin

EPS (Diluted)

$0.83

QoQ Revenue Growth

-5.0%

Cash Flow

Operating Cash Flow

$143M

Free Cash Flow

-$23M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$50.0B

Total Liabilities

$28.9B

Stockholders' Equity

$21.1B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$4.3B	-10.7%
Gross Profit	$1.3B	$1.5B	-17.6%
Operating Income	-$201M	-$78M	-159.4%
Net Income	$1.0B	-$264M	+483.3%

Revenue Segments

Brands

$2.3B60%

Generics

$1.3B34%

Complex GX and Biosimilars

$248M6%

Geographic Segments

Developed Markets Segment

$2.4B62%

Emerging Markets Segment

$581M15%

Greater China Segment

$506M13%

Japan, Australia and New Zealand Segment

$399M10%